Publication: Electroconvulsive therapy or clozapine for adolescents with treatment-resistant schizophrenia: An explorative analysis on symptom dimensions
No Thumbnail Available
Date
2022-12-27
Authors
Authors
Tunçtürk, Mustafa
Ermis, Çağatay
Büyüktaşkın, Dicle
Turan, Serkan
Sağlam, Yeşim
Alarslan, Sezen
Güler, Duru
Sut, Ekin
Unutmaz, Güldal
Güzel, Ayse Beste
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis Ltd
Abstract
ObjectiveThis study sought to compare pre-intervention patient characteristics and post-intervention outcomes in a naturalistic sample of adolescent inpatients with treatment-resistant psychotic symptoms who received either electroconvulsive therapy (ECT) or clozapine.MethodsData of adolescents with schizophrenia/schizoaffective disorder receiving ECT or clozapine were retrospectively collected from two tertiary-care psychiatry-teaching university hospitals. Subscale scores of the Positive and Negative Symptom Scale (PANSS) factors were calculated according to the five-factor solution. Baseline demographics, illness characteristics, and post-intervention outcomes were compared.ResultsThere was no significant difference between patients receiving ECT (n = 13) and clozapine (n = 66) in terms of age, sex, and the duration of hospital stay. The ECT group more commonly had higher overall illness and aggression severity. Smoking was less frequent in the clozapine group. Baseline resistance/excitement symptom severity was significantly higher in the ECT group, while positive, negative, affect, disorganisation, and total symptom scores were not. Both interventions provided a significant reduction in PANSS scores with large effect sizes.ConclusionBoth ECT and clozapine yielded high effectiveness rates in adolescents with treatment-resistant schizophrenia/schizoaffective disorder. Youth receiving ECT were generally more activated than those who received clozapine.
Description
Keywords
Antipsychotic-drugs, Double-blind, Children, Augmentation, Ect, Guidelines, Initiation, Disorders, Psychosis, Spectrum, Clozapine, Schizoaffective disorder, Treatment-resistant schizophrenia, Psychiatry